Vomiting News and Research RSS Feed - Vomiting News and Research

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.
Study suggests that antibiotics may help fight norovirus

Study suggests that antibiotics may help fight norovirus

Antibiotics aren't supposed to be effective against viruses. But new evidence in mice suggests antibiotics may help fight norovirus, a highly contagious gastrointestinal virus, report scientists at Washington University School of Medicine in St. Louis. [More]

Virginia Tech researchers call for critical review of EPA's secondary standards for drinking water

Changes in drinking water quality in the 21st Century are coming from a myriad of circumstances, and not all are for the best. Top contenders for why water-drinking quality might become suspect to the average consumer include California's drought conditions, the technology of fracking, and the nationwide aging infrastructure of rusty, degrading pipes. [More]
Altos Therapeutics announces issuance of Mexican patent covering dopamine D2/D3 drug candidates

Altos Therapeutics announces issuance of Mexican patent covering dopamine D2/D3 drug candidates

Altos Therapeutics, LLC announced today that the Mexican Institute of Industrial Property has issued Patent Number 323020 titled, "D2 Antagonists, Methods of Synthesis and Methods of Use". The patent broadly and specifically covers the company's dopamine D2/D3 drug candidates, their pharmaceutical compositions, and their use to treat a number of important gastrointestinal conditions in humans, such as gastroparesis. [More]
FDA approves RYTARY for Parkinson's disease treatment

FDA approves RYTARY for Parkinson's disease treatment

Impax Pharmaceuticals, a division of Impax Laboratories, Inc., today announced that the U.S. Food and Drug Administration approved RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication. [More]
FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, has received approval from the U.S. Food and Drug Administration for Dyloject (diclofenac sodium) Injection, a proprietary nonsteroidal anti-inflammatory drug (NSAID) analgesic. [More]
Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV. [More]
FDA approves Novo Nordisk’s weight loss injection, Saxenda

FDA approves Novo Nordisk’s weight loss injection, Saxenda

Novo Nordisk today announced that the Food and Drug Administration (FDA) has approved the new drug application (NDA) for Saxenda® (liraglutide [rDNA origin] injection), the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management. [More]
Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

AbbVie receives Health Canada approval for HOLKIRA PAK (ombitasvir/paritaprevir/ritonavir film-coated tablets; dasabuvir film-coated tablets), an all-oral, short-course (12 weeks for the majority of patients), interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with cirrhosis. [More]
Keryx Biopharmaceuticals supplies AURYXIA tablets to wholesalers in US

Keryx Biopharmaceuticals supplies AURYXIA tablets to wholesalers in US

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) (the "Company") today announced it has begun shipping AURYXIA™ (ferric citrate) tablets to wholesalers in the U.S. Auryxia is approved for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. [More]
FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

The U.S. Food and Drug Administration has approved AbbVie's VIEKIRA PAK, an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis. [More]
FDA approves intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi)

FDA approves intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi)

Jazz Pharmaceuticals plc today announced that the U.S. Food and Drug Administration approved the intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi). Erwinaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase. [More]
UT Southwestern researchers identify cell signaling mechanism that plays vital role in brain cancer

UT Southwestern researchers identify cell signaling mechanism that plays vital role in brain cancer

UT Southwestern Medical Center neurology researchers have identified an important cell signaling mechanism that plays an important role in brain cancer and may provide a new therapeutic target. [More]
Crealta publishes review of post-hoc safety analysis completed for Krystexxa

Crealta publishes review of post-hoc safety analysis completed for Krystexxa

Crealta Pharmaceuticals LLC, today announced that the Journal of Clinical Rheumatology published a comprehensive review of a post-hoc safety analysis that was completed for Krystexxa (pegloticase), including data from the two pivotal randomized Phase III trials and one open-label extension trial. [More]
Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Pharmacyclics, Inc. today announced that it has been awarded BayBio's 2014 Pantheon DiNA Award for Outstanding Company for its rapid development and commercialization of IMBRUVICA (ibrutinib). The award was presented at BayBio's 11th Annual Pantheon DiNA Awards ceremony in San Francisco. [More]
Figitumumab development discontinued for non-adenocarcinoma NSCLC

Figitumumab development discontinued for non-adenocarcinoma NSCLC

Adding the novel insulin-like growth factor 1 receptor inhibitor figitumumab to the epidermal growth factor receptor–tyrosine kinase inhibitor erlotinib does not improve survival in patients with non-adenocarcinoma non-small-cell lung carcinoma, research shows. [More]
MSU researchers find possible way to boost healthy cell production in cancer patients during chemo

MSU researchers find possible way to boost healthy cell production in cancer patients during chemo

Michigan State University scientists are closer to discovering a possible way to boost healthy cell production in cancer patients as they receive chemotherapy. By adding thymine - a natural building block found in DNA - into normal cells, they found it stimulated gene production and caused them to multiply. [More]
Research highlights potential of computers to enhance quality of care, medical outcomes

Research highlights potential of computers to enhance quality of care, medical outcomes

A computer system was more effective than doctors at collecting information about patient symptoms, producing reports that were more complete, organized and useful than narratives generated by physicians during office visits, according to a Cedars-Sinai study. [More]
Laughing gas could be used as treatment for severe depression

Laughing gas could be used as treatment for severe depression

Nitrous oxide, or laughing gas, has shown early promise as a potential treatment for severe depression in patients whose symptoms don't respond to standard therapies. The pilot study, at Washington University School of Medicine in St. Louis, is believed to be the first research in which patients with depression were given laughing gas. [More]
IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL). [More]
Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p). [More]